ANAB
AnaptysBio, Inc. Healthcare - Biotechnology Investor Relations →
AnaptysBio, Inc. (ANAB) closed at $66.76 as of 2026-05-01, trading 266.5% above its 200-week moving average of $18.21. The stock moved further from the line this week, up from 228.0% last week. With a 14-week RSI of 86, ANAB is in overbought territory.
Trading volume is running at 0.9x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.88 ratio) is neutral — neither side is clearly dominating.
Over the past 435 weeks of data, ANAB has crossed below its 200-week moving average 8 times. On average, these episodes lasted 37 weeks. The average one-year return after crossing below was -28.6%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $1943 million, ANAB is a small-cap stock. The company generates a free cash flow yield of 1.0%. Return on equity stands at -24.5%. The stock trades at 50.3x book value.
Over the past 8.3 years, a hypothetical investment of $100 in ANAB would have grown to $96, compared to $290 for the S&P 500. ANAB has returned -0.5% annualized vs 13.6% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ANAB vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ANAB Crosses Below the Line?
Across 8 historical episodes, buying ANAB when it crossed below its 200-week moving average produced an average return of -29.4% after 12 months (median -34.0%), compared to +13.3% for the S&P 500 over the same periods. 14% of those episodes were profitable after one year. After 24 months, the average return was +16.2% vs +43.6% for the index.
Each line shows $100 invested at the moment ANAB crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
ANAB has crossed below its 200-week MA 8 times with an average 1-year return of +-28.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Dec 2018 | Dec 2018 | 2 | 13.7% | -71.3% | +80.8% |
| Mar 2019 | Mar 2019 | 1 | 1.3% | -71.4% | +57.1% |
| Jun 2019 | Jan 2024 | 239 | 83.7% | -62.3% | +69.0% |
| Feb 2024 | Feb 2024 | 1 | 2.5% | -36.6% | +335.2% |
| Mar 2024 | May 2024 | 9 | 16.6% | -28.7% | +327.0% |
| Jun 2024 | Jun 2024 | 3 | 2.2% | +1.2% | +327.4% |
| Oct 2024 | Jul 2025 | 36 | 47.3% | +68.7% | +361.9% |
| Aug 2025 | Sep 2025 | 8 | 15.9% | N/A | +376.2% |
| Average | 37 | — | +-28.6% | — |
Frequently Asked Questions
Is ANAB below its 200-week moving average?
No. AnaptysBio, Inc. (ANAB) is currently 266.5% above its 200-week moving average of $18.21. It would need to fall to $18.21 to cross below the line.
What is ANAB's 200-week moving average price?
AnaptysBio, Inc.'s 200-week moving average is $18.21 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ANAB drops below its 200-week moving average?
ANAB has crossed below its 200-week moving average 8 times in our data. The average one-year return after these crossings was -28.6%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 37 weeks on average.
Is ANAB a good value right now?
Here's what our data says about ANAB as of 2026-05-01: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 86 (overbought). Free cash flow yield is 1.0%. Return on equity is -24.5%. Price-to-book is 50.3x. This is not a buy or sell recommendation — always do your own research.
How does ANAB compare to the S&P 500?
Over the past 8.3 years, $100 invested in ANAB would have grown to $96, compared to $290 for the S&P 500. That's -0.5% annualized vs 13.6% for the index. ANAB has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-01